PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28542039-0	2017	Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3"-ethynylcytidine treatment of human cancer cells.	1-(3-C-ethynylribopentofuranosyl)cytosine	80-98	uridine-cytidine kinase 2	Homo sapiens	12-37
21798026-0	2011	A nucleoside anticancer drug, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.	1-(3-C-ethynylribopentofuranosyl)cytosine	30-80	LOW QUALITY PROTEIN: breast cancer type 2 susceptibility protein	Cricetulus griseus	136-141
18854835-0	2008	Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo.	1-(3-C-ethynylribopentofuranosyl)cytosine	48-54	hypoxia inducible factor 1 subunit alpha	Homo sapiens	14-24
21798026-0	2011	A nucleoside anticancer drug, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.	1-(3-C-ethynylribopentofuranosyl)cytosine	82-88	LOW QUALITY PROTEIN: breast cancer type 2 susceptibility protein	Cricetulus griseus	136-141
21798026-12	2011	CONCLUSIONS: Our results indicate that TAS106 induces the down-regulation of BRCA2 and the subsequent abrogation of the HR pathway, leading to a radiosensitizing effect.	1-(3-C-ethynylribopentofuranosyl)cytosine	39-45	LOW QUALITY PROTEIN: breast cancer type 2 susceptibility protein	Cricetulus griseus	77-82
20219441-0	2010	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.	1-(3-C-ethynylribopentofuranosyl)cytosine	44-94	TP53 induced glycolysis regulatory phosphatase	Homo sapiens	132-179
20219441-0	2010	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.	1-(3-C-ethynylribopentofuranosyl)cytosine	44-94	TP53 induced glycolysis regulatory phosphatase	Homo sapiens	181-186
19360349-5	2009	TAS-106 potently inhibited the expression of Chk1 protein and the phosphorylation of Chk1 and Chk2.	1-(3-C-ethynylribopentofuranosyl)cytosine	0-7	checkpoint kinase 1	Homo sapiens	45-49
19360349-5	2009	TAS-106 potently inhibited the expression of Chk1 protein and the phosphorylation of Chk1 and Chk2.	1-(3-C-ethynylribopentofuranosyl)cytosine	0-7	checkpoint kinase 1	Homo sapiens	85-89
19360349-5	2009	TAS-106 potently inhibited the expression of Chk1 protein and the phosphorylation of Chk1 and Chk2.	1-(3-C-ethynylribopentofuranosyl)cytosine	0-7	checkpoint kinase 2	Homo sapiens	94-98
19360349-7	2009	In vivo, TAS-106 alone showed antitumor activity; however, its combination with CDDP significantly enhanced the growth inhibition of OCC-1 and LX-1 tumors.	1-(3-C-ethynylribopentofuranosyl)cytosine	9-16	follistatin like 1	Homo sapiens	133-138
19360349-8	2009	Moreover, combination therapy with TAS-106 and CDDP in the OCC-1 xenograft model resulted in significant life-prolongation.	1-(3-C-ethynylribopentofuranosyl)cytosine	35-42	follistatin like 1	Homo sapiens	59-64
20875083-2	2010	Previously, we showed that RNase L can be activated in human cancer cell line HT1080 by an RNA polymerase I inhibitor, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (3"-ethynylcytidine; ECyd).	1-(3-C-ethynylribopentofuranosyl)cytosine	119-169	ribonuclease L	Homo sapiens	27-34
20875083-2	2010	Previously, we showed that RNase L can be activated in human cancer cell line HT1080 by an RNA polymerase I inhibitor, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (3"-ethynylcytidine; ECyd).	1-(3-C-ethynylribopentofuranosyl)cytosine	171-189	ribonuclease L	Homo sapiens	27-34
20875083-2	2010	Previously, we showed that RNase L can be activated in human cancer cell line HT1080 by an RNA polymerase I inhibitor, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (3"-ethynylcytidine; ECyd).	1-(3-C-ethynylribopentofuranosyl)cytosine	191-195	ribonuclease L	Homo sapiens	27-34
18668243-0	2009	Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.	1-(3-C-ethynylribopentofuranosyl)cytosine	40-90	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	8-15
18854835-4	2008	At the same time, the accumulation of HIF-1alpha observed under hypoxia was shown to be decreased to the level of normoxia in the presence of 0.1 microM TAS106.	1-(3-C-ethynylribopentofuranosyl)cytosine	153-159	hypoxia inducible factor 1 subunit alpha	Homo sapiens	38-48
18854835-8	2008	These results suggest the possibility that TAS106 acts as a potent radiosensitiser through the inhibition of HIF-1alpha expression and can be a useful agent against radiotherapy-resistant hypoxic cells in solid tumours.	1-(3-C-ethynylribopentofuranosyl)cytosine	43-49	hypoxia inducible factor 1 subunit alpha	Homo sapiens	109-119
17711502-4	2007	The chemosensitivity of TMK-1 cells expressing hENT1 and hENT2 to cytarabine and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) cytosine increased markedly in comparison to that of mock cells.	1-(3-C-ethynylribopentofuranosyl)cytosine	81-131	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	47-52
17711502-4	2007	The chemosensitivity of TMK-1 cells expressing hENT1 and hENT2 to cytarabine and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) cytosine increased markedly in comparison to that of mock cells.	1-(3-C-ethynylribopentofuranosyl)cytosine	81-131	solute carrier family 29 member 2	Homo sapiens	57-62
18029773-0	2007	A novel apoptotic pathway of 3"-Ethynylcytidine(ECyd) involving the inhibition of RNA synthesis--the possibility of RNase L activated pathway as a target of ECyd.	1-(3-C-ethynylribopentofuranosyl)cytosine	29-47	ribonuclease L	Homo sapiens	116-123
17448876-11	2007	The inhibition of survivin expression by TAS106 is thought to mainly contribute to the suppression of the tumor growth.	1-(3-C-ethynylribopentofuranosyl)cytosine	41-47	baculoviral IAP repeat-containing 5	Mus musculus	18-26
18029773-9	2007	Moreover, Protein X was phosphorylated during the activation of RNase L by treatment with cytotoxic agent, ECyd, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine and 2-5A.	1-(3-C-ethynylribopentofuranosyl)cytosine	107-111	ribonuclease L	Homo sapiens	64-71
18029773-9	2007	Moreover, Protein X was phosphorylated during the activation of RNase L by treatment with cytotoxic agent, ECyd, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine and 2-5A.	1-(3-C-ethynylribopentofuranosyl)cytosine	113-164	ribonuclease L	Homo sapiens	64-71
17150838-0	2006	An apoptotic pathway of 3"-Ethynylcytidine(ECyd) involving the inhibition of RNA synthesis mediated by RNase L.	1-(3-C-ethynylribopentofuranosyl)cytosine	24-42	ribonuclease L	Homo sapiens	103-110
17150838-0	2006	An apoptotic pathway of 3"-Ethynylcytidine(ECyd) involving the inhibition of RNA synthesis mediated by RNase L.	1-(3-C-ethynylribopentofuranosyl)cytosine	43-47	ribonuclease L	Homo sapiens	103-110
15966763-5	2005	Western blot analysis proved that TAS106 treatment down-regulated the expression of the G2/M arrest-related proteins cyclin B1, phospho-CDC2 and WEE1.	1-(3-C-ethynylribopentofuranosyl)cytosine	34-40	G2/mitotic-specific cyclin-B1	Cricetulus griseus	117-126
15966763-5	2005	Western blot analysis proved that TAS106 treatment down-regulated the expression of the G2/M arrest-related proteins cyclin B1, phospho-CDC2 and WEE1.	1-(3-C-ethynylribopentofuranosyl)cytosine	34-40	wee1-like protein kinase	Cricetulus griseus	145-149
12903193-1	2002	We investigated single nucleotide polymorphisms (SNPs) in uck2 gene encoding metabolic enzyme of 3"-ethynylcytidine (ECyd) which were associated with drug response of ECyd, and the newly synthesized antitumor ribonucleoside analog.	1-(3-C-ethynylribopentofuranosyl)cytosine	97-115	uridine-cytidine kinase 2	Homo sapiens	58-62